(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for 6 well known Amusement Park - 2Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- 3Tesla plans to expand production at German car plant
- 4Exploring the Gig Economy: Examples from Consultants
- 5Brazil approves law strengthening protective measures for female victims of gender-based violence
- Wizz CEO: We’re going to invest $1 b. in Israeli market
- Manual for Vegetarian Protein Powder
- Israeli forces kill one person in series of attacks on southern Lebanon
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
